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Summary
Huntington disease (HD) is an autosomal dominant neu-
rodegenerative disorder characterized by motor distur-
bance, cognitive loss, and psychiatric manifestations.
The disease is associated with a CAG trinucleotide–
repeat expansion in the Huntington gene (IT15) on chro-
mosome 4p16.3. One family with a history of HD was
referred to us initially for predictive testing using linkage
analysis. However, the chromosome 4p region was com-
pletely excluded by polymorphic markers, and later no
CAG-repeat expansion in the HD gene was detected. To
map the disease trait segregating in this family, whole-
genome screening with highly polymorphic dinucleotide-
, trinucleotide-, and tetranucleotide-repeat DNA mark-
ers was performed. A positive LOD score of 3.01 was
obtained for the marker D20S482 on chromosome 20p,
by two-point LOD-score analysis with the MLINK pro-
gram. Haplotype analysis indicated that the gene re-
sponsible for the disease is likely located in a 2.7-cM
region between the markers D20S193 and D20S895.
Candidate genes from the mapping region were screened
for mutations.
Introduction
Huntington disease (HD; MIM 143100) is an autosomal
dominant neurodegenerative disorder with a disease fre-
quency of 1/10,000 individuals and onset usually in mid-
life. The mutation responsible for HD is an expansion
of a CAG repeat 135 repeats, at the 5′ end of the HD
gene (The Huntington’s Disease Collaborative Research
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Group 1993). Although this mutation has been identified
in most patients diagnosed with HD, there is a small
minority of the patients in whom no CAG amplification
in the HD gene can be detected. In a large study of 1,007
patients with a clinical diagnosis of HD, no CAG-repeat
expansion was found in 12 patients (Kremer et al. 1994).
In at least three families, linkage studies excluded
changes in the HD gene as being associated with this
phenotype (Andrew et al. 1994).
One of these families was referred to us for linkage
analysis in the predictive-testing program for HD in
1991. This family comprises 21 individuals in three gen-
erations. Seven of the family members were affected, and
their condition was diagnosed as HD because of its clin-
ical and neuropathological similarities to HD. The re-
gion containing the HD gene was, however, completely
excluded by linkage analysis using polymorphic markers
on chromosome 4p. Later, no CAG-repeat expansion in
the HD gene was detected in the affected individuals
(16–22 CAG repeats). Taken together, the data indicated
that changes in the HD gene are not associated with the
neurodegenerative disease in this family. Therefore, the
family might have an HD-like neurodegenerative dis-
order. To map the genetic locus of the disease, a whole-
genomic screen was undertaken.
Subjects, Material, and Methods
Patient Material
All members of the family that we studied originate
from Sweden. Genomic DNA was isolated from pe-
ripheral blood and from Epstein-Barr virus (EBV)–
transformed lymphoblastoid cell lines for all living in-
dividuals. Paraffin-embedded material was collected
from deceased individuals.
Genotype Analysis
A total of 391 microsatellite markers from Cooper-
ative Human Linkage Center (CHLC) Human Screening
Set/Weber version 6 and additional markers from Re-
search Genetics, Inc. (Dib et al. 1996) were used. Gen-
otypes were determined by PCR amplification using 33P-
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Table 1
Clinical and Neuropathological Features of the Affected Family Members
STATUS OF SUBJECTa
I-2 II-2 II:6 III-1 III-3 III-8 III-10
Age at HD onset (years) 41 28 29 23 29 29 29
Age at death or present age (years)b 52 42 43 46 39 36 32
Duration (years) 11 14 14 23
Clinical features:
Motor disturbances:
Rigidity   ND    ND
Choreic movements       
Coordination problems       
Dysarthria       
Ataxia ND   ND ND ND ND
Psychiatric disturbances:
Depression ND ND     ND
Aggressiveness      ND ND
Personality changes ND   ND  ND ND
Cognitive impairment       ND
Epileptic seizures ND   NA  ND ND
Neuropathology:
Basal-ganglia atrophy    NA NA NA NA
Frontal-lobe atrophy  ND  NA NA NA NA
Temporal-lobe atrophy    NA NA NA NA
Cortical atrophy    NA NA NA NA
Occipital-lobe atrophy  ND  NA NA NA NA
Plaques and tangles   ND NA NA NA NA
Neuroimaging (CT/MRI) NA NA NA Large ventricles Temporal-
lobe atrophy
Wide sulci NA
EEG NA NA Encephalopathy Encephalopathy Abnormal NA NA
a A plus sign () denotes presence of feature, and a minus sign () denotes its absence. ND  not described/unknown, and
NA  not available.
b Ages at death are underlined.
labeled primers. PCR reactions were performed on
96-well microtiter plates in 10-ml reaction volumes: 50
ng of genomic DNA, 2 pmol of each primer, and 0.5
unit of DynaZyme (Finnzymes Oy). The PCR cycle con-
ditions were 95C for 1 min, 55C–60C for 1 min, and
72C for 1 min, with a final extension of 72C for 7
min. The PCR products were separated on 6% dena-
turing polyacrylamide gels, and the alleles were visual-
ized by autoradiography.
Two-Point Linkage Analysis
Two-point LOD scores were calculated by the MLINK
program as implemented in the FASTLINK software
package, version 3.0P (Lathrop and Lalouel 1984; Cot-
tingham et al. 1993; Terwilliger and Ott 1994). The
frequency of this disease gene was assumed to be 1/
10,000 in the population, and the inheritance pattern
was considered to be autosomal dominant with a 100%
penetrance.
Sequence Analysis
PCR amplifications were performed on either genomic
DNA (if the exon/intron boundaries were known) or
cDNA. PCR products were used for heteroduplex anal-
ysis and sequencing. Heteroduplex analyses were per-
formed by an MDE heteroduplex kit (FMC Bioprod-
ucts). DNA from both strands was sequenced by a cycle
sequencing kit (Perkin-Elmer, Amersham Life Science),
according to the manufacturer’s instructions.
Results
Clinical Features of the Affected Family Members
Clinical and neuropathological findings are summa-
rized in table 1. Subject I-2 became aggressive, anxious,
and restless at age 41 years. Four years later, he was
admitted to a hospital because of intellectual dysfunc-
tion, delusional thoughts, an unstable gait, and elements
of chorea, rigidity, grimacing, and slurred speech. No
tremor was noted. Anticholinergic medication had no
effect. At the age of 51 years, his choreic movements
increased, and 1 year later he died. Autopsy and his-
topathology showed chronic encephalitis with cell loss
and gliosis in the basal ganglia, but no pathological
changes in the cerebrum, cerebellum, pons, medulla ob-
longata, or cortex were seen.
Xiang et al.: HD-Like Neurodegenerative Disorder 1433
Subject II-2 presented with personality changes, ag-
gressiveness, and dementia at age 28 years. Two years
later, she had an unsteady gait, expressionless face, and
dysarthria with some features of rigidity. Her condition
was diagnosed as “atypical HD.” Later she developed
epileptic seizures, and her choreic movements became
worse. She died at age 42 years. “Brain atrophy” in the
cerebral cortex, caudate nuclei, and globus pallidus and
more extensive atrophy in the temporal lobe were found,
and her brain weight was 960 g. The remaining neurons
showed a pronounced accumulation of lipofuscin pig-
ment. The thalamus and substantia nigra were intact,
whereas the cerebellum showed a slight loss of Purkinje
cells and mild gliosis in the molecular layer. However,
no signs of advanced degeneration of the cerebellum
were found, and no senile plaques or fibrillary degen-
eration was found. Extensive muscle atrophy and mye-
lopathy (degeneration of the nerve cells in the ventral
horns of the spinal cord) were noted. A diagnosis of HD
with some atypical features was made.
Subject II-6 was assessed at age 30 years for problems
of coordination, dysarthria, depression, and aggressive-
ness. Psychology tests showed “global cognitive impair-
ment.” An electroencephalogram (EEG) yielded patho-
logical findings, probably due to encephalopathy. Within
the next couple of years, she developed ataxia, an un-
steady swaying gait, and jerky, clumsy movements, and
her condition was diagnosed as probable HD. Later she
developed epileptic seizures, and she died at age 43 years.
Autopsy showed loss of body weight (27 kg) and brain
weight (950 g). Her brain atrophy was diffuse and sym-
metric, particularly in the frontal and occipital lobes,
with a thin cortex and atrophy of caudate nuclei. The
substantia nigra, cerebellum, and brain stem were nor-
mal. Microscopic examination revealed gliosis and foci
of extensive degeneration in the basal ganglia.
Subject III-1, who was depressed and disoriented at
age 23 years and who was assessed for cognitive decline,
was diagnosed as having possible HD, on the basis of
cognitive impairment and family history of HD. An EEG
showed mild or moderate diffuse encephalopathy. Six
years later, however, an unsteady gait and obvious jerks
in the arms and legs were noted. Over time the choreic
movements worsened, and they were accompanied by
further intellectual dysfunction and aggressiveness. A
computed tomographic (CT) scan showed bilaterally
widened ventricles but no other pathological findings.
Subject III-3 developed personality changes (apathy
and difficulties with daily activities) and aggressiveness
at age 29 years. Three years later, this person was ad-
mitted to a hospital because of increasing memory prob-
lems and signs of speech disturbances. A CT scan
showed central and peripheral atrophy of the brain and
reduction of the temporal lobes. The subject’s condition
was diagnosed as presenile dementia of unknown cause
(no family history of HD was known to the foster par-
ents). Over time, subject III-3 showed significant dete-
rioration, including muteness, a stiff gait, dysphagia, and
occasional epileptic seizures.
Subject III-8 requested predictive testing for HD in
1991, at age 30 years. No obvious dystonia or chorea
was observed. Muscular tone, tendon reflexes, cerebellar
functions, eye movements, and sensory functions were
normal. However, this patient had noted difficulties in
walking down stairs and increasing problems with co-
ordination. Subject III-8 was mildly depressed, and cog-
nitive performance was significantly impaired. Drawing,
writing, and calculation tests were poorly performed. A
magnetic-resonance imaging (MRI) scan of the brain re-
vealed widened sulci of the convexity, but the neostria-
tum was normal (fig. 1). The symptoms showed signif-
icant progression, with worsening of speech and
deterioration in fine motor abilities. This individual is
now in extended home care and can say only a couple
of words.
Subject III-10 has had symptoms similar to those of
subject III-8 (poor handwriting, gait disturbances, and
speech problems) for ∼3 years, although no diagnosis
has been made.
Review of Neuropathological Material
Autopsy material, preserved as slides for subjects I-2,
II-2, and II-6, was reviewed again by an experienced
neuropathologist and a neurologist, and previous find-
ings were confirmed. In summary, pathological changes
consistent with HD were found—namely, pronounced
neuronal loss and gliosis in the basal ganglia and cortical
atrophy. However, both the generalized cortical atrophy
with very low brain weight in subjects II-2 and II-6 and
the temporal-lobe atrophy in subjects II-2 and III-3 are
more atypical findings, as is the myelopathy seen in sub-
ject II-2. The substantia nigra was preserved in all cases,
and no senile plaques or fibrillary tangles were found.
There were no pathological changes consistent with
dentatorubral-pallidoluysian atrophy (DRPLA; MIM
125370). Multisystem atrophy with striato-nigral de-
generation was also excluded, since the substantia nigra
was intact.
Other diagnoses that have significant clinical similar-
ities to HD, such as spinocerebellar ataxia 3 (SCA-3;
MIM 109150), spinocerebellar ataxia 2 (SCA-2; MIM
183090), and DRPLA, were excluded by DNA testing.
Chorea-acanthocytosis (CHAC; MIM 200150) was ex-
cluded by cytological analysis of the red blood cells. No
diagnostic alternative to HD could be suggested.
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Figure 1 MRI of subject III-8. A, Normal neostriatum. B, Widened sulci of convexity, indicating cortical atrophy.
Genetic Analysis of the Family, and Exclusion of the
HIP1 Gene
Whole-genome screening using the CHLC Human
Screening Set/Weber version 6 was performed. The
screening set consists of 391 markers with an average
interval of 10 cM. Most chromosomes were completely
excluded by haplotype and linkage analysis (LOD score
!2). A few regions on chromosomes 7–9 and 12 were
not excluded, since the markers were not informative
enough. A weak positive LOD score was obtained with
marker D7S1816. The huntingtin interacting protein–1
(HIP1; MIM 601767) gene, which interacts with hun-
tingtin, was mapped close to D7S1816 (Kalchman et al.
1997). The genomic structure and exon/intron bound-
aries of HIP1 were determined, and all the exons of the
HIP1 gene were analyzed by sequencing and heterodu-
plex analysis (A. H. M. M. Huq, K. Nichol, L. R. Os-
borne, S. W. Scherer, E. W. Almqvist, F. Squitieri, M.
Anvret, T. S. Ross, L.-C. Tsui, and M. R. Hayden, un-
published data). No mutation in the HIP1 gene was de-
tected in the affected family members. Additional highly
informative markers from these regions were used in
order to either confirm or exclude the respective region.
Haplotype analysis of these regions on chromosomes
7–9 and 12 also excluded them as candidates.
Mapping to Chromosome 20p
Haplotype analysis showed that affected individuals
in the family shared the same haplotype for several
markers on chromosome 20p. However, a normal in-
dividual (subject II-8) who is still unaffected at the age
of 50 years inherited the same haplotype as was seen in
the affected individuals. An individual at this age and
with this haplotype would be expected to show some
symptoms, since the disease is considered to be fully
penetrant. The origin of the identical haplotype shared
by the affected individuals and normal individual II-8
cannot be determined, since the affected grandfather was
homozygous for several markers in this region. There-
fore, an additional 30 highly polymorphic markers at
high density in the region were employed. Haplotype
analysis indicated that all the affected individuals share
the same haplotype for markers from loci D20S97
through D20S892 (fig. 2), which originated from the
affected grandfather (subject I-2). Subject II-8, who
is normal, shares, between markers D20S895 and
D20S892, the same haplotype as is seen in the affected
individuals, suggesting that recombination has occurred
close to marker D20S895. The only common region
shared by affected individuals should be from D20S97
to D20S889. Linkage analysis shows that the LOD score
reached 3.01, at a recombination fraction of .0, for the
most informative marker, D20S482 (fig. 3 and table 2).
This is the highest LOD score predicted by simulation
test. The variation in LOD scores for markers D20S181,
D20S116, D20S97, D20S482, and D20S889 was due to
the uninformativeness of the markers in some family
members. The disease locus in the family is likely to be
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Figure 2 Pedigree and haplotypes of family studied. The haplotype associated with the disease is boxed. The pedigree has been changed
to protect confidentiality. Subject I-3 is still unaffected at 91 years of age.
located in the chromosomal region from D20S193 to
D20S895, spanning only 2.7 cM (fig. 4).
Evaluation of Candidate Genes on 20p
In the mapped region of chromosome 20, there are
several genes that play critical roles in normal neural
function and can be implicated as possible candidate
genes for this condition, such as the prion gene, SNAP25,
CCA12, preproenkephalin B, and the transglutaminase
3 gene.
The prion gene consists of two exons, and the protein
is coded by the second exon (Puckett et al. 1991). The
whole coding region was completely sequenced by PCR
amplification, and no mutation or abnormal repeat in
the gene was detected.
The SNAP25 gene encodes a 25-kD protein and was
first investigated as a neuron-specific gene preferentially
expressed in CA3 pyramidal neurons of mouse hippo-
campus. The human SNAP25 and mSNAP25 showed
perfect amino acid sequence conservation (Zhao et al.
1994). The whole coding sequence (nucleotides 206–
823) was completely sequenced by reverse transcrip-
tion–PCR, but no mutation was found.
The human preproenkephalin B gene is known to con-
tain the determinants for neoendorphin, dynorphin, and
leumorphin. These opioid peptides, each with a leucine-
enkephalin structure, act on the kappa receptor (Hori-
kawa et al. 1983). No changes were found in the coding
region of this gene, by sequencing of cDNA from EBV-
transformed lymphoblastoid.
The CCA12 transcript contains a CCA repeat and
maps to this region (The Human Gene Map). No var-
iation in the repeat size between affected and normal
individuals in this family was detected by PCR ampli-
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Figure 3 Genotype of marker D20S482. Affected individuals are
marked with an asterisk (*).
Table 2
Pairwise LOD Score of Markers on Chromosome 20p
MARKER
LOD SCORE AT RECOMBINATION FRACTION OF
.0 .01 .05 .10 .20 .30 .40
D20S906  .37 .93 1.05 .96 .72 .40
D20S181 1.00 .98 .92 .83 .65 .46 .24
D20S193  .67 1.21 1.30 1.16 .87 .47
D20S97 .78 .77 .72 .66 .52 .37 .20
D20S482 3.01 2.96 2.74 2.47 1.87 1.24 .58
D20S889 1.81 1.78 1.67 1.53 1.22 .88 .48
D20S895  .96 1.47 1.51 1.29 .92 .48
D20S849  .07 .63 .75 .68 .48 .25
D20S835 .48 .50 .55 .55 .44 .28 .12
D20S873  .53 .05 .19 .18 .08 .01
D20S882 .90 .89 .82 .73 .54 .36 .18
D20S916 1.89 1.86 1.74 1.58 1.25 .89 .48
D20S905  .96 1.47 1.51 1.29 .92 .48
D20S194  .01 .73 .98 1.01 .80 .46
D20S892  .96 1.47 1.52 1.30 .93 .49
fication. Other candidate genes, such as transglutami-
nase 3 and bone morphogenetic protein–2, are in the
process of being screened.
Discussion
The diagnosis of HD in this family was first made in
the 1960s, in two sisters (subjects II-2 and II-6). The
rapid progression of dementia early in the disease, which
is atypical of HD, could be consistent with early-onset
familial Alzheimer disease (MIM 104311). However,
this diagnosis could not be confirmed by neuropatho-
logical changes such as senile plaques or neurofibrillary
tangles. The clinical features in the affected family mem-
bers are similar to those of frontotemporal dementia
(FTD; MIM 601630). However, FTD usually has a
slower progression, with preserved spatial orientation
(The Lund and Manchester Groups 1994). In addition,
in contrast to the family in the present study, atrophy
of the striatum is usually not seen, and the substantia
nigra shows neuronal loss. In some families, FTD maps
to chromosome 17 (Yamaoka et al. 1996; Heutink et al.
1997), but linkage to this region could not be verified
in this family. All affected individuals presented with
dysarthria and problems with coordination at onset and,
later, with both choreic movement, seen in the classic
presentation of HD, and neuropathological findings con-
sistent with HD. However, some subjects presented with
epileptic seizures, which is unusual for adult-onset HD,
and they do not show the CAG expansion in the HD
gene. It is clear that in this family there is no other HD-
gene mutation causing this disease, since the HD locus
was excluded by linkage analysis. The positive LOD
score of 3.01 on chromosome 20p suggests, instead, that
in this family the mutation that is responsible for this
phenotype is likely in another gene.
Affected individuals in this family show some features
of anticipation (i.e., decreasing age at onset in successive
generations). Thus far, 112 human diseases that are
caused by trinucleotide-repeat expansions in the respec-
tive gene have been identified (Reddy and Housman
1997; Ross 1997), most of them associated with antic-
ipation. It could therefore be possible that the causative
mutation in this family is a trinucleotide expansion. PCR
analysis was performed to assess possible variation in
the size of the CCA repeat (human transcript CCA12)
that is located in this region. However, no variation in
its size was observed among affected and normal indi-
viduals, and it can be excluded as the disease-associated
mutation in this family.
The prion diseases are a group of unusual degenerative
diseases affecting both humans and animals, which in-
volve the CNS and always result in a fatal outcome
(Prusiner 1996). The human prion diseases are caused
by mutations in the prion gene on chromosome 20p.
The majority of the mutations are missense mutations,
a 144-bp insertion or an extra-tandem repeat (octapep-
tide coding repeat) between codons 51 and 91. The clin-
ical features of the prion diseases do vary to a great
extent from one individual to the next. To a certain
degree, the clinical picture in this family overlapped with
that of prion diseases. The prion gene is located to the
same region (from marker D20S97 to marker D20S95;
The Human Gene Map) as in the family in which we
mapped the disease locus. However, no substitution, in-
sertion, or extra-tandem repeat in the coding sequence
of the prion gene was identified in the affected individ-
uals. Therefore, the prion gene is unlikely to be a can-
didate gene for the disease.
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Figure 4 Map of chromosome 20 and localization of markers.
The order and distance (in cM) are based on the data from Ge´ne´thon.
Recently, Hallervorden-Spatz syndrome (HSS; MIM
234100) was mapped to the same 20p region by ho-
mozygosity mapping (Taylor et al. 1996). HSS is an au-
tosomal recessive neurodegenerative disorder character-
ized by increasing dysarthria, progressive dementia and
rigidity, and involuntary movements, with onset in child-
hood. Mental deterioration and epilepsy are also seen
in some cases, and histologic study has shown massive
iron deposits in the basal ganglia. Pathological brain iron
accumulation occurs in several common disorders, such
as Parkinson disease, Alzheimer disease, and HD. Al-
though the affected individuals in this family do share
several common symptoms with HSS, in HSS the in-
heritance is recessive, whereas it is clearly dominant in
this family. It is possible that a heterozygous mutation
in the HSS gene could cause a milder, late-onset neu-
rodegenerative disorder. An example would be por-
phyria catanea tarda (PCT; MIM 176100), a late
adult–onset disorder due to a heterozygous mutation in
the uroporphyrinogen decarboxylase gene, whereas a
homozygous mutation in the same gene causes hepa-
toerythropoietic porphyria (HEP; MIM 176100), which
is a more severe disorder and has onset of symptoms in
infancy (de Verneuil et al. 1988; Garey et al. 1989).
Thus, different mutations in the same gene could be
responsible for both HSS and the HD-like neurodegen-
erative disorder in this family.
Although the mutation causing HD has been identified
as a CAG expansion in the HD gene, the mechanism by
which CAG expansion leads to neurodegeneration is not
clearly understood. It has been proposed that the ex-
panded glutamine repeats in huntingtin could result in
the precipitation of the huntingtin protein in specific
neurons, causing the observed selective neuronal loss
(apoptosis) (Igarashi et al. 1998; Martindale et al. 1998).
Identification of the genes that are responsible for HD-
like neurodegenerative disorders may provide useful ad-
ditional information for understanding the molecular
mechanisms and pathways underlying this disorder as-
sociated with selective neuronal loss in the basal ganglia.
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